BiotechTube
Altay Therapeutics

Altay Therapeutics

San Diego, United States· Est. 2020

Altay Therapeutics is a private, preclinical-stage biotech focused on unlocking transcription factors as therapeutic targets. The company's core technology is a therapeutic area-agnostic platform that identifies novel allosteric sites on transcription factors to design highly selective oral inhibitors. With its lead FSHD program expected to enter IND-enabling studies in 2025 and a STAT3 inhibitor in lead optimization, Altay is positioning itself as a leader in a challenging but high-potential drug discovery space, supported by grants and recognition from major pharmaceutical companies.

altaytherapeutics.com

Private Company

Total funding raised: $31.3M

AI Company Overview

Altay Therapeutics is a private, preclinical-stage biotech focused on unlocking transcription factors as therapeutic targets. The company's core technology is a therapeutic area-agnostic platform that identifies novel allosteric sites on transcription factors to design highly selective oral inhibitors. With its lead FSHD program expected to enter IND-enabling studies in 2025 and a STAT3 inhibitor in lead optimization, Altay is positioning itself as a leader in a challenging but high-potential drug discovery space, supported by grants and recognition from major pharmaceutical companies.

Muscular DystrophyOncologyInflammatory Diseases

Technology Platform

A therapeutic area-agnostic drug discovery platform that identifies novel allosteric sites emerging from dynamic structural changes in transcription factors, enabling the design of highly selective oral small molecule inhibitors.

Funding History

6
Total raised:$31.3M
Grant$300KMay 10, 2024
Grant$400KSep 19, 2022
Grant$300KAug 29, 2022
Grant$299KMay 19, 2022

Opportunities

The primary opportunity is to establish a new class of oral therapeutics for diseases driven by dysregulated transcription factors, starting with FSHD—a rare disease with no approved treatments.
Success with the platform could enable rapid expansion into large markets in oncology (via STAT3 and undisclosed targets) and chronic inflammation.
Being first with an oral DUX4 inhibitor could command premium pricing and rapid adoption in the FSHD community.

Risk Factors

The key risks are scientific: the novel platform may not successfully translate from preclinical models to human efficacy and safety.
The company faces competition from well-funded biotechs using alternative modalities (e.g., oligonucleotides) in FSHD.
As a private, preclinical-stage company, it carries significant financing risk and depends on raising capital to reach clinical milestones.

Competitive Landscape

In FSHD, Altay competes with Dyne Therapeutics and Avidity Biosciences, who are developing injectable oligonucleotide therapies targeting DUX4. Altay's oral small molecule offers a key differentiation in convenience. In STAT3 inhibition, it competes in a challenging field with companies like Tvardi Therapeutics; differentiation will depend on demonstrating superior potency, selectivity, and clinical safety. Altay's platform approach is its main competitive moat if validated.